We evaluated the predictive ability of cystatin C and creatinine-based estimations of glomerular filtration rate (eGFR), including the Chronic Kidney Disease-Epidemiology (CKD-EPI) equation, in acute coronary syndrome (ACS) patients with (STE-ACS) or without (NSTE-ACS) ST elevation in a large contemporary ACS population.
METHODS:
Concentrations of cystatin C and creatinine, as well as eGFR at randomization, were measured in 16 401 patients in the Platelet Inhibition and Patient Outcomes (PLATO) study and evaluated as predictors of the composite end point of cardiovascular death or myocardial infarction within 1 year. Two Cox proportional hazards models were used, the first adjusting for clinical characteristics and the second for clinical characteristics plus the biomarkers N-terminal pro-B-type natriuretic peptide, troponin I, and C-reactive protein.
RESULTS:
The median cystatin C value was 0.83 mg/L. Increasing quartiles of cystatin C were strongly associated with poor outcome (6.9%, 7.1%, 9.5%, and 16.2%). The fully adjusted hazard ratios per SD of cystatin C in the NSTE-ACS and STE-ACS populations were 1.12 (95% CI 1.04 -1.20) (n ϭ 8053) and 1.06 (95% CI 0.97-1.17) (n ϭ 5278), respectively. There was no significant relationship of cystatin C with type of ACS (STE or NSTE). c Statistics ranged from 0.6923 (cystatin C) to 0.6941 (CKD-EPI).
CONCLUSIONS: Cystatin C concentration contributes independently in predicting the risk of cardiovascular death or myocardial infarction in NSTE-ACS, with no interaction by type of ACS. CKD-EPI exhibited the largest predictive value of all renal markers. Nevertheless, the additive predictive value of cystatin C or creatinine-based eGFR measures in the unselected ACS patient is small.
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Cystatin C is a cysteine protease inhibitor involved in the catabolism of proteins and is synthesized in all nucleated cells at a constant rate (1, 2 ) . This 13-kDa protein exhibits favorable characteristics for a renal biomarker since it is freely filtrated by the glomerulus, nearly completely reabsorbed and catabolized in the proximal tubule, and subsequently does not return to the blood (1, 3 ) . Plasma cystatin C concentrations are closely related to the glomerular filtration rate (GFR) 10 , reflecting renal function. Recent studies have found concentrations of cystatin C, like creatinine, to be affected by some nonrenal factors such as age and sex (4, 5 ) . Cystatin C is considered equivalent or even superior to other renal markers such as creatinine or creatinine-based estimations of GFR by the Cockcroft-Gault equation (C-G) (6 ) or the Modification of Diet in Renal Disease equation (MDRD) (1, 3, 4, (7) (8) (9) (10) . However, cystatin C has not been tested against the Chronic Kidney Disease-Epidemiology equation (CKD-EPI), which is considered more reliable for estimation of glomerular filtration in patients with normal or nearnormal renal function (10 ) .
Even a small decrease in GFR estimated by C-G, MDRD, or cystatin C is associated with an increased risk for death and cardiovascular disease (7, 8, (11) (12) (13) (14) (15) (16) (17) . Concentrations of cystatin C have been related to both mortality and myocardial infarction rates in a non-STelevation acute coronary syndrome (NSTE-ACS) population (16 ) . However, the relation between concentrations of cystatin C and outcomes in a STE-ACS population is unclear (18 ) , and the predictive value of CKD-EPI in patients with ACS has not been investigated. The Platelet Inhibition and Patient Outcomes (PLATO) trial (19, 20 ) randomized a broad population with ACS, including both NSTE-ACS and STE-ACS, to antiplatelet treatment with ticagrelor vs clopidogrel during 6 -12 months of follow-up. In the present substudy, we aimed to assess and compare the predictive power of cystatin C and estimated GFR by creatinine-based equations (C-G, MDRD, and CKD-EPI).
Methods

DESIGN AND STUDY POPULATION
The details of the PLATO design and results have been reported (19, 20 ) . In brief, the double-blind multicenter PLATO trial randomized a broad ACS population (n ϭ 18 624) with or without ST-segment elevation on admission to receive antiplatelet therapy with either clopidogrel or ticagrelor on top of aspirin and optimal medical therapy and, to a high extent, catheterization and revascularization (20 ) .
] (19 ) was 1 of several high-risk criteria that formed the basis for inclusion, whereas renal failure requiring dialysis was an exclusion criterion (19 ) .
SAMPLING AND LABORATORY ANALYSIS
Blood samples were obtained via a direct venous puncture from 16 401 patients at the time of randomization. The blood samples were gently inverted and centrifuged at 2000g. Plasma was removed, equally distributed in transfer tubes, and frozen at Ϫ20°C. All blood samples were shipped to Quintiles core laboratories, where N-terminal pro-B-type natriuretic peptide (NTproBNP) and creatinine were analyzed. Troponin I, high-sensitivity C-reactive protein (hsCRP), and cystatin C were analyzed at the central laboratory at the Uppsala Clinical Research Center (Uppsala, Sweden), and the specimens were stored in the Uppsala Clinical Research Center biobank.
We measured plasma cystatin C on the Abbot Architect CI-8200, which was also used for the measurement of hsCRP. The analytical imprecision for cystatin C was 1.94% at the mean of 0.87 mg/L and 2.49% at 2.91 mg/L (total run) with the assay from Gentian (21 ). We measured plasma NT-proBNP on the Roche Cobas instrument and plasma troponin I on the Beckman Coulter Access system. Serum creatinine was measured in a core laboratory by a rate-blanked and compensated modified Jaffe method with the Roche BMD instrument. The method was standardized to isotope-dilution mass spectrometry (ID-MS), and the analytical imprecision for creatinine was 0.7% at 148 mol/L (1.67 mg/dL) (intraassay) and 2.3% at 96 mol/L (1.09 mg/dL) (interassay).
We calculated cystatin C-derived estimated GFR (eGFR) was calculated using the formula by the manufacturer Gentian: 79.901 ϫ Cyst
Ϫ1.4389
, where Cyst is plasma cystatin C in mg/L (21 ) .
The GFR from C-G was calculated as: ). To overcome some of the limitations with either cystatin C-derived eGFR or creatinine-based eGFR, combinations were also assessed. One combination was a progressive eGFR in which cystatin C-based calculations contributed solely to low eGFRs and CKD-EPI-based calculations contributed solely to high [Ͼ120 mL ⅐ min
] eGFRs. We hypothesized that the progressive cystatin C/CKD-EPI formula would benefit from the strengths of the 2 different equations regarding each equation's strongest interval for GFR assessment.
STATISTICAL ANALYSIS
The prespecified primary end point of the present substudy, as well as of the overall biomarker program, was the combination of cardiovascular death and myocardial infarction within 1 year of follow-up. Cardiovascular death and myocardial infarction were also separately evaluated. Stroke was excluded because of few events and different pathophysiological mechanisms.
Baseline characteristics were summarized by quartile of cystatin C using frequencies for categorical variables and medians with interquartile intervals for continuous variables.
We analyzed cystatin C and CKD-EPI regarding outcome with Cox proportional hazards models. The first model included clinical risk factors [age, sex, body mass index, randomized treatment, type of ACS, cystatin C or CKD-EPI (dependent variable), habitual smoking] and previous conditions (heart failure, diabetes, hypertension, nonhemorrhagic stroke, myocardial infarction, peripheral artery disease, coronary artery bypass grafting, percutaneous coronary intervention). The second model included all the above risk markers plus biomarkers log(NT-proBNP), log(CRP), and troponin I dichotomized at 0.08 g/L (20 ) . To avoid potential covariation with the renal function parameters, chronic renal disease, defined as known GFR Ͻ60 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 , was not included in either of the models.
Cystatin C measured at the time of randomization and CKD-EPI calculated with creatinine at randomization were each evaluated as a continuous variable (log transformed) and dichotomized at optimal cutoff using the integrated discrimination improvement (IDI) measure (22 ) . Cystatin C was also evaluated as quartiles. The treatment effect in relation to concentration of cystatin C was evaluated with Cox proportional hazards model, with treatment group, log(cystatin C), and their interaction as dependent variables. Modeladjusted hazard ratios were derived along with 95% CIs. We assessed the proportional hazards assumption with respect to cystatin C by visually inspecting the log cumulative hazard plots and by extending the Cox model with a time-by-cystatin C interaction factor. Proportional hazards were assumed. The overall analysis set consisted of all patients who had been randomly assigned to a treatment group and received at least 1 dose of study medication.
We assessed the predictive values of cystatin C and the 4 GFR measures (C-G, MDRD, CKD-EPI, and cystatin C-derived eGFR) with the c statistic [area under the ROC curve (AUC)] according to the method of DeLong et al. (23 ) and by IDI (22 ) . To facilitate interpretation of the results, we calculated the relative IDI (22 ) . The c statistic was derived for the full analysis set as well as in 2 groups with GFR above or below 60 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 , defined by cystatin C-derived GFR.
P values Ͻ0.05 were considered statistically significant. All analyses were done with SAS software (version 9.2, SAS Institute).
Results
RENAL FUNCTION AT BASELINE
The median plasma cystatin C concentration was 0. Patients with increased markers of renal function were older and more seldom smokers but at higher cardiovascular risk (Table 1). Female sex was more common with high cystatin C but with low serum creatinine concentrations ( Table 1) .
The median GFR derived from cystatin C in the total population was 104 mL ⅐ min Ϫ1 with cystatin C-derived GFR was 65% of the study population, whereas both CKD-EPI and C-G showed a proportion of 36%. The proportion of patients with an eGFR of Ͼ120 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 was 38.0% with cystatin C, 8.5% with C-G, and 0.7% with CKD-EPI. The proportions of patients in CKD class 3 or greater (GFR Ͻ60 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 ) were 12.0%, 21.3%, and 18.6% with cystatin C, C-G and CKD-EPI, respectively. The proportions of patients in CKD class 4 or greater (GFR Ͻ30 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 ) were 1.4%, 1.4%, and 1.6%.
PLASMA CYSTATIN C CONCENTRATIONS AND OUTCOME
Higher cystatin C concentrations were associated with increased risk for the composite outcome of cardiovascular mortality or myocardial infarction, both when evaluated as a continuous variable (Table 2 ) and as quartiles (Fig. 1) . Yearly Kaplan-Meier event rates for increasing quartiles were, 6.9%, 7.1%, 9.5%, and 16.2% respectively.
The increasing risk was sustained after multivariable adjustment for both the entire ACS population and the NSTE-ACS subgroup (Table 2 ). This was even more pronounced when using the IDI optimal cutoff (1.11 mg/L) ( Table 2 ).
In the numerically smaller STE-ACS subset, after multivariable adjustment including biomarkers, the risk was consistent with the NSTE-ACS results but without reaching statistical significance (Table 2) . There was no relationship with type of ACS (P ϭ 0.36). The risk associated with higher concentrations of cystatin C was not significantly affected by the randomized treatment, and both investigational treatments showed similarly higher event rates with increasing quartiles of cystatin C at admission (data not shown).
The hazard ratio (HR) per 0.35 mg/L increase in cystatin C for cardiovascular death alone within the entire ACS population was 1.45 (95% CI 1.35-1.57) when adjusting for clinical variables and 1.11 (95% CI 1.02-1.22) after the addition of biomarkers to the multivariable analysis (not shown). Kaplan-Meier curves are shown in Supplemental Fig. 1 , which accompanies the online version of this article at http://www. clinchem.org/content/vol58/issue1. The corresponding HR for the STE-ACS patients regarding cardiovascular death alone was 1.39 (1.25-1.56) and 1.01 (0.89 -1.15), when using the first and second statistical model, respectively. The corresponding hazard ratios of the NSTE-ACS patients regarding cardiovascular death alone were 1.50 (1.36 -1.65) and 1.19 (1.07-1.32), respectively. There was no significant relationship with type of ACS. The HRs per 0.35 mg/L increase in cystatin C regarding myocardial infarction alone within the entire ACS population were 1.12 (1.04 -1.20) with adjustment for clinical variables and 1.08 (1.00 -1.17, P ϭ 0.0488) with multivariable adjustment (data not shown). The results for the STE-ACS and NSTE-ACS subgroups were consistent with the main results without reaching statistical significance.
COMPARISON OF THE PREDICTIVE VALUE FOR CREATININE-
BASED eGFR MEASURES
There were nearly identical c statistics for the different renal biomarkers or GFR measures, with CKD-EPI achieving the numerically highest AUC values ( Fig.  2A,B) . In the more sensitive IDI measure, CKD-EPI received the highest relative IDI of 4.8% when adjusted for both clinical variables and biomarkers. Cystatin C alone and cystatin C-derived GFR received the lowest relative IDI (3.3% and 2.8%). The combination of cystatin C and CKD-EPI did not increase the predictive properties of CKD-EPI alone. The Cockcroft-Gault equation, which has been shown to be more predictive of cardiovascular complications than MDRD (24 ) , had a lower predictive capability (3.7%) than CKD-EPI but was stronger than cystatin C.
Neither cystatin C nor any creatinine-based GFR measure increased the AUC significantly compared to a multivariable analysis without a renal marker (Fig.  2B) .
CKD-EPI AND OUTCOME
The CKD-EPI equation showed the highest relative IDI values. Cox regression analysis of the entire ACS population regarding the primary end point showed that the HR per SD of CKD-EPI was 1.25 (95% CI 1.19 -1.32) for the clinical model and 1.15 (1.09 -1.22) after the addition of biomarkers. In the STE-ACS population, the corresponding HRs regarding the primary composite end point were 1.24 (1.14 -1.35) and 1.11 (1.01-1.22) and for the NSTE-ACS population 1.26 (1.19 -1.33) and 1.16 (1.09 -1.24). With the use of IDI, the optimal cutoff for discrimination with the CKD-EPI was 60.3 mL ⅐ min Ϫ1 ⅐ (1.73m 2 )
Ϫ1
. The HR for the dichotomized analysis using this cutpoint was 1.65 (1.45-1.87), and after the addition of biomarkers, the HR was 1.40 (1.22-1.60).
EFFECT OF RANDOMIZED TREATMENT IN RELATION TO RENAL
FUNCTION
The benefit of ticagrelor compared to clopidogrel in reducing the primary composite end point (cardiovascular death or myocardial infarction) of the current substudy tended to be greater with lower renal function (defined as higher concentrations of cystatin C) (Fig.  3) ; however, there was no significant relationship with the type of treatment (P ϭ 0.27).
Discussion
In our study, cystatin C appeared to be an independent risk variable for the composite end point of cardiovascular death or myocardial infarction during 1 year of follow-up in all types of ACS. The combined risk for either cardiovascular death or myocardial infarction increased by a relative 10% per SD of cystatin C. Dichotomized at the IDI optimal cutoff (1.11 mg/L), patients above the cutpoint experienced a relative 21% higher event rate. The predictive value was more prominent in the NSTE-ACS subgroup, but the results were consistent in the numerically smaller STE-ACS subgroup. Cystatin C was also associated with higher risk for cardiovascular death alone, but not for myocardial infarction alone.
All renal markers in this study gave similar contributions to overall risk prediction, although there was a small numerical advantage for CKD-EPI, which was an independent variable for risk stratification in both STE-ACS and NSTE-ACS.
The additive predictive value of a renal marker in this population without markedly impaired renal function to a multivariable analysis was small and of marginal clinical importance. Only reduced renal function corresponding to a cystatin C concentration of Ͼ1 mg/L seemed to increase the risk. CKD-EPI exhibited the highest prognostic value and, at the IDI calculated cutoff of 60.3 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 )
Ϫ1
, indicated a Number of patients at risk is below.
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relative risk increase of 40% for patients with an eGFR below this value. The value of cystatin C and other renal markers was diminished in combination with other biomarkers, especially NT-proBNP, which exhibits a very powerful association with mortality and thereby increased the predictive ability compared to clinical variables alone. Cystatin C has previously shown to be a clinically significant predictor of cardiovascular death in both ACS populations and apparently healthy individuals (15) (16) (17) . Our results confirm cystatin C as an independent variable, but we were not able to detect a strong correlation between renal function assessment and outcome. Rather we found the predictive value of renal assessment in general, and cystatin C assessment in particular, to be low in our population.
Our results, based on the largest cohort of ACS patients studied, partly differ from previously reported studies. Possible explanations can be found in differences between the studies such as the type of cohort studied, baseline variables, and treatment strategies. Our study was characterized by high median renal function and a large percentage of smokers and patients with diabetes, whereas median age, proportion of women, and event rates were low by comparison (15) (16) (17) .
Cystatin C was significantly associated with mortality in a study that investigated apparently healthy patients (high proportion of women) with a mean age of 75 years (none Ͻ65 years) for a median of 7.4 years between 1993 and 2001 (17 ) . Cystatin C was reported as quintiles with a median value of 1.05 mg/L. Approximately 40% of the patients had a cystatin C Ͻ1.0 mg/L (considered low risk), compared to almost threequarters of the patients in our study. The authors reported a strong relationship with mortality but a weaker link to myocardial infarction, possible owing to the large number of deaths compared to myocardial infarctions in the study (17 ) . This may be important, bacause cystatin C, NT-proBNP, and troponin I are primarily related to mortality, with weaker associations to myocardial infarction.
In a coronary care unit population, cystatin C was reported as an independent risk predictor (15 ) . This population was older and more evenly balanced between the sexes and had fewer comorbidities compared to our population. The renal function was worse, and the follow-up regarding mortality longer (40 months). The results showed a strong relationship between cystatin C and death, although myocardial infarction, during 6 months' follow up, was not independently significant (15 ) .
In a coronary artery disease population followed for 3.7 years, cystatin C was also an independent risk variable for cardiovascular mortality (25 ) . The magni- tude of the risk was greater than in our study, but major differences include a low proportion of ACS, a majority of patients treated with single antiplatelet therapy or none, and no patients with GFR Ͻ60 mL ⅐ min Ϫ1 ⅐ (1.73m 2 ) Ϫ1 (25 ) . Finally, in an NSTE-ACS population, cystatin C was an independent predictor for both mortality and myocardial infarction. This study exclusively included troponin I-positive patients, a large group was noninvasively managed, and the follow-up was longer, factors subsequently leading to a higher event rate (16 ) .
The large proportion of STE-ACS patients with relatively low long-term risk in our study may have diluted the predictive effect of renal function markers in our study. Another contributing factor may be the low rate of cerebrovascular events and subsequent cardiovascular death in our study. Other potential limitations are that 88.1% of the patients had baseline creatinine and cystatin C samples and that although multivariable adjustment was performed, factors influencing cystatin C concentrations such as amount of smoking, body constitution, and thyroid status, or the influence on both creatinine and cystatin C by nonrenal factors as age, sex, or race, may have affected the results (4, 5 ) .
The advantage of ticagrelor over clopidogrel in reducing adverse cardiac events tends to increase with renal dysfunction, as estimated with C-G and MDRD (14 ) . These findings are now also verified with renal function estimated with cystatin C.
Renal function estimation remains important to predict risk, decide treatment strategies, and guide pharmacological dosing. Previous studies have shown the Cockcroft-Gault equation to be superior for risk prediction (13, 24 ) , and it has by tradition been used for pharmacological dosing and clinical guidance. MDRD is supported by the US Food and Drug Administration for renal function assessment (26 ) but has been challenged by the CKD-EPI, which is more accurate (10 ). In our study, with a high median estimated GFR, we have shown that different equations heterogeneously classified renal function, especially in the patients with GFR Ͼ60 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 . It is likely that these differences have affected the predictive value of the equations, possibly in favor of CKD-EPI, which has been validated in a large number of individuals with normal renal function.
The present study showed statistically significant but clinically limited usefulness of cystatin C as an incremental risk predictor in patients with acute coronary syndrome. We thereby found no evidence supporting the clinical use of cystatin C, alone or in combination, instead of other renal markers or GFR measures for risk stratification in ACS patients. Instead, the CKD-EPI seems to be a better predictor for adverse events and produced a clinical relevant cutpoint with increased risk for all ACS patients with a GFR Ͻ60 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 .
Summary
In this large contemporary ACS population, cystatin C concentrations contributed independently in predicting the risk of cardiovascular death or myocardial in-farction, with no interaction by type of ACS. Of all renal markers and estimations analyzed, the strongest predictive value was found in the CKD-EPI equation, which was an independent risk variable in both STE-ACS and NSTE-ACS patients, where an estimated GFR of Ͻ60.3 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 was associated with a crude relative 40% increased risk for the composite end point compared to patients without renal dysfunction.
Although the additive power of cystatin C or any GFR measurement to a multivariate analysis was significant, the magnitude of the additional value of any renal marker to overall risk prediction is low when clinical risk factors and biomarkers of myocardial infarction and left ventricular dysfunction are used in the prediction model.
